Monitoring Atrial Fibrillation After Catheter Ablation

Giovanni B Forleo, MD, PhD1, Michela Casella, MD, PhD2, Antonio Dello Russo, MD, PhD2, Massimo Moltrasio, MD2, Gaetano Fassini, MD2, Manfredi Tesauro, MD, PhD1, Claudio Tondo, MD, PhD2

1Policlinico Universitario Tor Vergata, Rome, Italy. 2Cardiac Arrhythmia Research Center, Centro Cardiologico Monzino IRCCS, Milan, Italy.

Abstract
Although catheter ablation is an effective treatment for recurrent atrial fibrillation (AF), there is no consensus on the definition of success or follow-up strategies. Symptoms are the major motivation for undergoing catheter ablation in patients with AF, however it is well known that reliance on perception of AF by patients after AF ablation results in an underestimation of recurrence of the arrhythmia. Because symptoms of AF occurrence may be misleading, a reliable assessment of rhythm outcome is essential for the definition of success in both clinical care and research trials.

Continuous rhythm monitoring over long periods of time is superior to intermittent recording using external monitors to detect the presence of AF episodes and to quantify the AF burden. Today, new devices implanted subcutaneously using a minimally invasive technique have been developed for continuous AF monitoring. Implantable devices keep detailed information about arrhythmia recurrences and might allow identification of very brief episodes of AF, the significance of which is still uncertain. In particular, it is not known whether there is any critical value of daily AF burden that has a prognostic significance. This issue remains an area of active discussion, debate and investigation. Further investigation is required to determine if continuous AF monitoring with implantable devices is effective in reducing stroke risk and facilitating maintenance of sinus rhythm after AF ablation.

Introduction
Atrial fibrillation (AF) is one of the major common and chronic disorders seen in clinical practice1 and it is associated with a reduced quality of life and an increased long-term risk of stroke, heart failure and all cause mortality.2-3 A number of controlled, and randomized clinical trials have consistently shown that catheter ablation is superior to antiarrhythmic pharmacological treatment in maintaining sinus rhythm among patients with symptomatic drug-refractory AF.4-10 Remarkably there is no consensus on the definition of success or follow-up strategies after AF ablation. Even brief asymptomatic episodes can substantially raise the risk of stroke, therefore a reliable evaluation of AF recurrences is crucial after AF ablation and may be useful in making clinical decisions.

Irrespective of symptoms, assessment of rhythm can be conducted with the use of intermittent (noninvasive) or continuous (implanted devices) monitoring systems. Increased duration of monitoring appears to be associated with increased rates of detection of AF and, on the basis of different monitoring techniques,11-12 sensitivity in detecting AF recurrences after catheter ablation is reported to range between 31% and 71% and negative predictive value between 21% and 65%.13

Non-Continuous AF Monitoring Systems
In addition to baseline ECG and symptom evaluation, several methods have been described to improve rhythm monitoring in AF patients. Intermittent monitoring includes periodical ECGs, Holter and event recorders with or without loop memory. The diagnostic accuracy of these methods is limited and it is well known that there is a clear relationship between the duration of monitoring and the diagnostic yield.

Follow-up evaluation after AF ablation has been traditionally performed by routine ECG recordings and ambulatory 24-hour Holter monitoring.14-16 Recently, new extended monitoring methods have been introduced, including trans-telephonic ECG transmissions, event recorders and external loop recorders. Systems without a loop memory allow intermittent rhythm monitoring and are useful to confirm recurrences in patients with symptoms suggestive
of AF. External loop recorder systems are ideal for capturing also asymptomatic AF recurrences; the ECG recording is triggered either automatically, according to the arrhythmia detection algorithm, or manually by the patient; besides device data can be stored on a memory card or sent through a telephone/internet connection.

The main drawback of these systems is that they are tolerated only by highly motivated patients over a short period of time (usually few months). Thus, non-implantable recording systems play a limited role for a reliable and continuous monitoring of post-ablation recurrences. Furthermore, patients with infrequent AF recurrences are the most difficult to identify with intermittent monitoring and face a significant thromboembolic (TE) risk in the absence of appropriate oral anticoagulation (OAC) therapy.

**Continuous AF Monitoring Systems**

Continuous AF monitoring can only be achieved through the diagnostics of implantable device, which can store significant information regarding heart rhythm. The first experience with continuous AF monitoring is derived from the analysis of data stored in dual-chamber pacemakers and implantable cardioverter-defibrillators (ICD) capable of arrhythmia monitoring. If the atrial rate exceeds a programmable value for a given period of time, an atrial arrhythmia will be detected allowing the assessment of AF episodes irrespective of associated symptoms.

The use of cardiac pacemaker as an implanted arrhythmia monitor has been first evaluated in the MOST trial. In a population of 312 pacemaker patients, this study evaluated the correlation between the presence of atrial high rate events (AHRE) and clinical outcomes. The presence of AHRE longer than 5 min was found to be an independent predictor of total mortality and non-fatal stroke. Similarly, other large prospective multi-centric studies have examined the relationship between AF episodes detected by implanted devices and patient outcomes (Table 1).

Dual-chamber pacemakers and implantable cardioverter-defibrillators allow direct recording of atrial electrograms, but those devices are clearly not the ideal arrhythmia surveillance method, mainly because of the presence of intracardiac leads. To provide continuous information on cardiac rhythm, implantable leadless cardiac monitoring systems (ICM) with specific AF detection algorithms have been developed. Automatic triggers with physician-programmable parameters allow AF episodes detection as well as AF burden quantification and batteries can last up to 5 to 6 years affording the possibility of prolonged continuous monitoring. The ICM memory can store both automatically detected AF episodes and a number of patient-activated episodes, which can be easily transmitted via telephone or internet to remotely and continuously evaluate a patient for AF recurrences after AF ablation.

The XPECT study evaluated for the first time the performance of an implantable leadless cardiac monitor (Reveal XT; Medtronic Inc.) with dedicated AF detection capabilities. The study showed that the overall accuracy of the ICM for detecting AF was 98.5% and the ICM-measured AF burden was very well correlated (Pearson coefficient \( r = 0.97 \)) with the reference value derived from Holter. Very recently, the CRYSTAL-AF study demonstrated that this system is more effective than standard non-invasive monitoring methods to find an AF episode in patients with cryptogenic stroke. This study included 441 patients randomized to Reveal-XT or standard cardiac monitoring within 90 days of a cryptogenic stroke. At 12 months, AF was detected in 12.4% of patients in the Reveal arm versus 2.0% of those in the control arm [HR 7.3 (95% CI 2.6-20.8, \( p < 0.0001 \)].

Implantable leadless device monitoring systems might override the problems related to the patient compliance and several data on continuous monitoring after AF ablation have recently been published. Verma et al. in a large multicentric prospective study evaluated the incidence of asymptomatic AF episodes before and after CA, as assessed by an implantable cardiac monitor with AF detection. In this study, ICM detected 12% of patients with purely asymptomatic AF and the ratio of asymptomatic to symptomatic AF episodes increase from 1.1 before to 3.7 after catheter ablation. Consistent with the results of this study, we have recently demonstrated in 145 patients with paroxysmal or persistent AF, that continuous ECG monitoring is a valuable tool for long-term follow-up after AF catheter ablation facilitating reliable assessment of symptomatic and asymptomatic AF episodes. Furthermore, Bogachev-Prokopiev et al. confirmed the reliability of subcutaneous continuous monitoring also in patients who had undergone surgical AF ablation.

**Is Procedural Success Truly Achieved Without Continuous AF Monitoring?**

The definition of “long-term ablation success” remains controversial. Guidelines state that the primary indication of AF ablation is to reduce AF-related symptoms and to improve quality of life. Secondary endpoints might include elimination of symptomatic AF and control of AF with previously ineffective antiarrhythmic drugs (AAD). The poor correlation between symptoms and AF should caution physicians against making clinical decisions depending on symptoms. Asymptomatic AF has been reported to be up to 12 times more frequent than symptomatic AF, even in patients with histories of symptomatic AF. Although ablation significantly reduces the burden of AF, the proportion of asymptomatic AF episodes increases, consequently the procedural success is overestimated by patient

---

**Table 1: Critical value of daily AT/AF burden: relationship with clinical events**

<table>
<thead>
<tr>
<th>Study, year</th>
<th>patients</th>
<th>Detection Methods</th>
<th>Follow-up</th>
<th>Endpoint</th>
<th>AT/AF burden cutoff</th>
<th>Hazard ratio and P</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MOST 2003</td>
<td>312</td>
<td>PM</td>
<td>27 months</td>
<td>Total mortality</td>
<td>&gt; 5 minutes</td>
<td>HR 2.48 ( P = 0.0092 )</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Death/non fatal stroke</td>
<td>&gt; 5 minutes</td>
<td>HR 2.79 ( P = 0.0011 )</td>
<td></td>
</tr>
<tr>
<td>Capucci et al. 2006</td>
<td>725</td>
<td>PM</td>
<td>22 months</td>
<td>Arterial embolism</td>
<td>&gt; 24 hours</td>
<td>HR 3.1</td>
<td>( p = 0.044 ) ( P = N S )</td>
</tr>
<tr>
<td>TRENDS 2009</td>
<td>2486</td>
<td>PM/ICD</td>
<td>1.4 years</td>
<td>Annualized TE rates</td>
<td>&lt; 5.5 hours</td>
<td>HR 0.98</td>
<td>( P = 0.97 )</td>
</tr>
<tr>
<td>ASSERT 2012</td>
<td>2580</td>
<td>PM/ICDor NSAIDs or alcohol</td>
<td>2.5 years</td>
<td>Ischemic stroke/ systemic embolism</td>
<td>&gt; 6 minutes</td>
<td>HR 5.56</td>
<td>( P &lt; 0.0001 )</td>
</tr>
<tr>
<td>SOST AF 2013</td>
<td>10016</td>
<td>PM/ICD</td>
<td>24 months</td>
<td>Ischaemic stroke</td>
<td>&gt; 5 minutes</td>
<td>HR 1.76</td>
<td>( P = 0.041 )</td>
</tr>
</tbody>
</table>

**Abbreviations:** AT/AF = atrial tachycardia/fibrillation; HR = Hazard Ratio; ICD = internal cardioverter-defibrillator; PM = pacemaker; TE = thromboembolic.
symptoms. Silent AF is likely to be associated with morbidity and mortality rates not inferior to symptomatic AF, therefore, a reliable rhythm outcome analysis after AF ablation has the potential to reduce that risk. Post-procedure arrhythmia monitoring is also useful because in a significant number of patients, palpitations may be misinterpreted as AF episodes; in one study, 40% of pacemaker patients reported symptoms suggestive of AF that were not confirmed neither by standard ECG recording nor device interrogation.

Emerging evidence suggests that sinus rhythm restoration following AF ablation can provide clinical and prognostic benefits. Winkle et al have recently demonstrated that patients with prior stroke, who under successful AF ablation, have a low incidence of subsequent thromboembolic events, and most of those patients may be able to discontinue OAC. The consistency of these findings suggests that restoration of sinus rhythm by catheter ablation might result in lower rates of stroke and death. Of note, the Heart Rhythm Society’s consensus document on AF ablation recommends that success can be defined as freedom from AF or atrial tachycardia, lasting 30 seconds 12 months after AF ablation. Intermittent and symptom-based monitoring is highly inaccurate for identifying patients with AF recurrences leaving untreated a vulnerable population. Thus, implantable devices are the most reliable method to precisely identify AF recurrences after AF ablation both in clinical care and in the setting of a clinical research study.

Estimating AF Burden: The Importance Of Cutoff Length

The unexpectedly high incidence of ICM-detected non-sustained atrial arrhythmias raises the question of whether there is any clinical significance to these, often asymptomatic, AF episodes. Quantitative AT/AF burden detected by implanted devices may be a thromboembolic (TE) risk element independent of standard stroke risk factors and absence of symptoms can even increase the thromboembolic risk if objective information on AF status is lacking.

Current guidelines do not specifically address any anticoagulation use in case of non-sustained device-detected AF episodes. Generally, it has been demonstrated that patients with AHREs, compared to those without AHREs, are more likely to have adverse clinical outcomes, including a higher incidence of stroke, death and subsequent AF. The adverse effects of paroxysmal AF have been correlated to the AF burden (Table 1). However, the amount of AF burden that has a prognostic significance. The main issue is that AF is responsible for an increased risk of stroke and death, and elimination of AF normalises that risk; therefore great attention should be paid to device-detected AF episodes and treatment should be delivered accordingly. A comprehensive evaluation should combine AF burden and TE risk.

Taken together these data from large cohorts of implanted patients add to the current evidence that measuring daily AF burden may have an important clinical relevance. New technologies of continuous rhythm monitoring might allow identification of very brief episodes of AF but is not known whether there is a critical value of daily AF burden that has a diagnostic significance. The main issue is that AF is responsible for an increased risk of stroke and death, and elimination of AF normalises that risk; therefore great attention should be paid to device-detected AF episodes and treatment should be delivered accordingly. A comprehensive evaluation should combine AF burden and TE risk.

Continuous AF Monitoring: Impacting Patient Outcomes

Atrial fibrillation ablation has the potential to restore sinus rhythm, eliminating the need for AADs and potentially for long-term anticoagulation. Because AF symptoms may be misleading, appropriate rhythm monitoring surveillance after AF ablation may help to guide clinical decision making in certain subsets of patients. The present evidence suggests that a highly accurate follow-up, as provided by implantable devices, may add significant information to current clinical risk stratification schemes. The device-stored data can also be evaluated with remote monitoring systems, which can allow a prompt clinical reaction and may reduce hospitalizations and costs.

Optimal post-procedural anticoagulation strategy is essential for minimising bleeding and thromboembolic risk after AF ablation. Hemorrhagic risk can be lowered by reducing unnecessary and prolonged OAC administration while the patient is in sinus rhythm. In patients with CHADS score ≤2, OAC are frequently discontinued after AF ablation if no recurrences have been documented during follow-up. In a large reported experience on 831 patients after AF ablation, warfarin was stopped within 12 months in 76.5% of patients with no arrhythmia recurrence. This approach is commonly performed despite the fact that patients are frequently followed-up with the use of limited temporal ECG monitoring duration. However, caution should be considered before OAC withdrawal because unrecognized recurrences might lead to devastating consequences, including death and thromboembolic stroke. If OAC are discontinued after AF ablation, the risk of asymptomatic AF recurrences cannot be ruled out without a continuous AF monitoring.
system.

The routine use of cardiac monitoring to identify AF patients who will benefit from anticoagulation has been reported to be cost-effective. Continuous AF monitoring with implanted devices increases sensitivity of AF detection when compared to conventional diagnostic methods and data transmission allows a remote and continuous evaluation for AF recurrences. Recently, the ANGELS of AF project demonstrated the possibility to improve OAC use as thrombo-prophylaxis through the use of information from ICD AF-diagnostics as compared with standard care.

Early diagnosis triggers earlier treatment and in this regard novel OAC (dabigatran, rivaroxaban and apixaban), which might be early self-administered without dose titration, allows for rapid onset anticoagulation with a single oral dose early after an AF episode. Current evidence suggests that a prothrombotic state is evident within minutes after the onset of an AF episode. Since left atrial thrombi can develop early during AF episodes, an early AF detection afforded by ICM might increase the safety of discontinuing OAC after AF ablation. The ongoing IMPACT trial has been designed to test the hypothesis that initiation or withdrawal of oral anticoagulant therapy guided by continuous ambulatory monitoring of the atrial intracardiac electrograms improves clinical outcomes. This study has the potential to provide some answers to this important question but it has been stopped early and remains unpublished.

Beyond implementation of appropriate anticoagulation, an early intervention following device-detected AF episodes has other potential benefits in improving the management of patients after AF ablation. It is likely that the benefits of sinus rhythm are in part counterbalanced by the potential adverse effects of long-term AAD use. The detailed rhythm information obtained through continuous monitoring might allow an earlier AAD discontinuation reducing the potential side effects of medications.

Brief and predominantly asymptomatic AF episodes may remain undetected until the next scheduled evaluation delaying the appropriate management of AF recurrences. Early diagnosis, through continuous AF monitoring, triggers earlier treatment and might also facilitate the self-administration of a single oral dose of Ic drug (pill-in-the-pocket) shortly after the onset of the AF recurrence. The prolonged duration of AF negatively effects electrical and structural atrial remodelling, therefore early restoration of sinus rhythm might have potential benefits over the long-term follow-up.

Optimal Time And Duration Of AF Monitoring

Limited data are available on the optimal time and duration of monitoring after AF ablation. Continuous AF monitoring might be useful both in the short-term and over the long-term follow-up after AF ablation. Early recurrences of AF are quite common in the so-called blanking period and are often asymptomatic. However, appropriate surveillance during the early post-ablation period may identify patients who are at a higher risk of long term treatment failure since early recurrences strongly predict a lack of long-term success.

Pokushalov et al. demonstrated in 286 patients continuously monitored through an implantable device after AF ablation, that this strategy might be useful for deciding whether to perform a second ablation or to implement drug therapy. In this study patients were treated according to the onset mechanism of AF recurrences, as detected and stored by the implantable cardiac monitor. They observed that patients with recurrences after the first AF ablation are likely to respond to a second early ablation when AF is triggered by supraventricular arrhythmias or premature contractions.

Several clinical studies assessing the long-term efficacy of catheter ablation procedures have reported late AF recurrences in patients who were initially considered responders to catheter ablation. Therefore, longer-term monitoring might identify AF episodes in patients in whom the OAC had been previously suspended. Because of the recognition of the late AF recurrences, the HRS/EHRA/ECAS consensus document on AF ablation concluded that a decision regarding OAC discontinuation should be based on the CHADS stroke risk score rather than the apparent efficacy of the AF ablation procedure.

False Positive Device-Detected Events

Long-term AF monitoring by implanted devices may be of substantial clinical value. However, its practical application may, in part, be limited by the prevalence of false-positive events. The risk of false-positives detections mainly generated by myopotential and motion artefacts still exists, highlighting the importance of human revaluation of automatically detected episode. False-positive events might lead to unscheduled evaluations in patients with remote follow-up that significantly increase the physician work burden. Unscheduled patient evaluation after ICM implantation has also a major impact on quality of life and cost-effectiveness in ICM recipients. Longer cutoff might result in a reduced number of false-positive events. An analysis from the ASSERT trial by using a cutoff of >6 minutes and >190 beats/min showed a 17.3% rate of false-positive AHREs, making physician review of electrograms essential. For AHREs lasting >6 hours, the rate of false positives is 3.3%, making physician review less crucial.

New sensing and detection algorithms for ICM have been developed in order to substantially reduce the occurrence of inappropriately detected AT/AF episodes. A higher specificity of the algorithm is necessary and would avoid unnecessary clinical evaluations once the alert system is activated. Future research will focus on optimal device programming that will offer maximal benefit, increasing the clinical utility of ICM algorithms.

Conclusions:

Because AF symptoms may be misleading, appropriate rhythm monitoring surveillance after AF ablation may help to guide clinical decision making in certain subsets of patients. The present evidence suggests that a highly accurate follow-up, as provided by implantable devices, may add significant information to current clinical risk stratification schemes.

Implantable devices keep detailed information about arrhythmia recurrences and might allow identification of very brief episodes of AF, the significance of which is still uncertain. In particular, it is not known whether there is a critical value of daily AF burden that has any prognostic significance. This issue remains an area of active discussion, debate and investigation. Further investigation is required to determine if continuous AF monitoring with implantable devices is effective in reducing stroke risk and facilitating maintenance of sinus rhythm after AF ablation.

References:

Reyes, C., et al. Natural history and long-term outcomes of ablated atrial fibrillation.


